Golden Horizon™: Public Benefit Allocation & Subsidized Precision Suites™ Allocation
DeepSensi PBC is a Delaware Public Benefit Corporation whose corporate charter enshrines the principle that breakthrough clinical intelligence must never be restricted only to those with unlimited means. While the standard institutional value of a full multi-system case evaluation and 12-month longitudinal tracking is $4,850, the Golden Horizon™ program provides an immense institutional research subsidy for up to 10,000 patients and families annually facing chronic, complex, or intractable diseases. Under this charter allocation, qualifying patients gain access to our elite Precision Medicine Suites™ at heavily subsidized protocol rates ($790), with a dedicated 100% Full Hardship Fee Waiver pathway for families with documented severe financial distress.
100% Full Hardship Fee Waiver Pathway (For Families in Acute Need). For patients and families facing severe economic vulnerability, the DeepSensi PBC Charter guarantees a complete 100% fee waiver ($0 fee). This pathway is open to households meeting any of the following criteria: (a) household income at or below 300% of the Federal Poverty Guidelines, (b) active enrollment in Medicaid, CHIP, or equivalent public assistance programs, or (c) documented catastrophic hardship, such as overwhelming out-of-pocket medical debt, loss of household income due to chronic illness, or long-term disability. Qualifying applicants receive full access to their designated Precision Suite cognitive evaluation and 12-month longitudinal registry tracking without any software cost.
The Bring-Your-Own-Diagnostics (BYOD) Rule. DeepSensi operates exclusively as a cognitive intelligence, multi-agent consilium, and clinical decision-support platform (SaMD / FDA Cures Act 520(o)). DeepSensi does not sell, conduct, or mark up physical laboratory assays. Under the BYOD model, the patient, family, and treating physician always provide their own certified local laboratory test results required for the specific Precision Suite (such as Organic Acids Tests [OAT], stool metagenomic sequencing, blood chemistry panels, or therapeutic drug monitoring). Testing must be conducted independently through certified accredited laboratories of your choice. This guarantees zero duplicate testing costs, zero lab markups, and full clinical integrity.
Direct Connection to Precision Suites. Golden Horizon directly bridges patients suffering from treatment-resistant conditions into the 11 specialized Precision Medicine Suites™ (spanning pediatric epilepsy, refractory autoimmunity, neuroinflammation, dysautonomia, metabolic disorders, and rare orphan diseases). The subsidy covers the cognitive software intake, multi-agent consilium synthesis, deterministic IEC 61025 SIL-4 safety audit, and 12-month longitudinal outcome tracking for your licensed treating physician.
Annual Charter Allocation (10,000 cases). Under the DeepSensi PBC charter, the program reserves an annual public benefit allocation of up to 10,000 subsidized protocol intakes per calendar year across active disease registries. Applications are evaluated strictly based on documented financial hardship, clinical tractability, and processing capacity. When the current cohort allocation is committed, completed applications enter an active waitlist and are allocated on a rolling basis. The program is currently open to applicants in the United States and Canada (excluding Quebec), expanding internationally as regulatory pathways open.
Scope of Subsidy or Hardship Waiver. An allocation covers one full case evaluation lifecycle and 12-month longitudinal tracking within the designated Precision Suite for one patient. A household may hold one subsidized protocol at a time. The subsidy does not renew automatically; families requiring ongoing annual re-evaluations may submit a renewal request evaluated on the same hardship criteria.
Who can apply. You live in an eligible jurisdiction; you are the patient (18 or older), a parent or guardian, or another legally authorized representative; the resulting clinical dossier will be delivered to a licensed treating physician; and your household meets either the general subsidy criteria or the 100% full hardship exemption criteria described above.
How decisions are made. Allocations are decided exclusively on clinical eligibility and financial need. Decisions are completely insulated from commercial considerations, physician referrals, or institutional sponsorships.
Financial documents. To decide an application we ask only for the household income documents or hardship statements listed in the application form. They are reviewed strictly by two compliance officers who decide the allocation. They are not used for any other purpose, are never shared with treating physicians, sponsors, investigators or registries, and do not affect the terms of any commercial deployment. They are kept for the period set out in our privacy notice and deleted securely thereafter.
Privacy & Zero-PHI Architecture. Application information is handled in DeepSensi's isolated identity and compliance systems, completely segregated from clinical diagnostic pipelines. Any health-related documentation submitted during hardship attestation is handled strictly under the Consumer Health Data Privacy Policy. Direct patient identifiers are removed on device before clinical data ingestion.
Timelines and appeals. Decisions are communicated within 10 business days of completed submission. If an application is declined, you may appeal within 30 days; an independent reviewer who took no part in the initial determination decides the appeal.
Truthfulness. Applicants must provide accurate and verifiable information. Subsidies or fee waivers obtained through fraudulent statements may be withdrawn.
Independence from research. Participation in clinical research registries sponsored by DeepSensi (such as the RESOLVE™ observational registries) is always 100% voluntary, free, and protected under ethical governance (IRB / 45 CFR 46). Participation in research gives no priority for Golden Horizon subsidies, and declining or leaving research never affects a subsidy or waiver. Golden Horizon governs subsidized access to cognitive decision-support software (Precision Suites™), which is strictly independent of voluntary registry participation. Section 6.7 and section 10 of the Terms of Service apply to this program in full.
Applications for the upcoming 10,000-case cohort allocation open concurrently with the launch of Precision Medicine Suites™.